Finance

Lists
Why is STAR down 2,17%?
Dive Deeper
STAR:NSE
Strides Pharma Science Ltd
1 014,80 INR
-2,17%
(-22,50) 1D
4-ноя., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
1 034,00 INR
High
1 047,80 INR
Low
1 010,00 INR
Mkt. cap
93,54 млд
Avg. vol.
349,71 миң
Volume
184,83 миң
Dividend
0,49%
Quarterly dividend
1,25 INR
Ex-dividend date
2026-ж., 31-июл.
P/E ratio
15,25
52-wk high
1 260,90 INR
52-wk low
768,65 INR
EPS
66,55 INR
Shares outstanding
89,55 млн
No. of employees
4 миң
Open
1 034,00 INR
High
1 047,80 INR
Low
1 010,00 INR
Mkt. cap
93,54 млд
Avg. vol.
349,71 миң
Volume
184,83 миң
Dividend
0,49%
Quarterly dividend
1,25 INR
Ex-dividend date
2026-ж., 31-июл.
P/E ratio
15,25
52-wk high
1 260,90 INR
52-wk low
768,65 INR
EPS
66,55 INR
Shares outstanding
89,55 млн
No. of employees
4 миң
News stories
From web sources and news partners
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3,54 миң
Founded1990
HeadquartersБенгалуру, Карнатака, Индия
SectorPharmaceutical industry
Industry-
Last report
2026-ж., 30-окт.
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
14,30 млд / 14,15 млд
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
11,95 млд
13,23 млд
12,65 млд
14,30 млд
Cost of goods sold
4,63 млд
7,19 млд
4,95 млд
6,29 млд
Cost of revenue
4,63 млд
7,19 млд
4,95 млд
6,29 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,30 млд
3,45 млд
2,43 млд
2,38 млд
Operating expense
5,46 млд
4,91 млд
5,97 млд
6,07 млд
Total operating expenses
10,09 млд
12,10 млд
10,92 млд
12,36 млд
Operating income
1,85 млд
1,13 млд
1,73 млд
1,94 млд
Other non operating income
1,07 млд
-1,66 млд
48,90 млн
40,83 млн
EBT including unusual items
2,45 млд
1,48 млд
2,00 млд
1,50 млд
EBT excluding unusual items
2,49 млд
502,07 млн
1,36 млд
1,52 млд
Income tax expense
373,53 млн
187,70 млн
341,23 млн
163,18 млн
Effective tax rate
15,22%
12,68%
17,09%
10,85%
Other operating expenses
2,66 млд
928,53 млн
2,97 млд
3,11 млд
Net income
2,02 млд
1,27 млд
1,57 млд
1,31 млд
Net profit margin
16,92%
9,59%
12,40%
9,15%
Earnings per share
-
-
-
-
Interest and investment income
-
404,82 млн
-
-
Interest expense
-433,79 млн
-130,82 млн
-405,61 млн
-465,41 млн
Net interest expenses
-433,79 млн
274,00 млн
-405,61 млн
-465,41 млн
Depreciation and amortization charges
506,23 млн
532,49 млн
563,99 млн
572,15 млн
EBITDA
2,25 млд
1,55 млд
2,15 млд
2,51 млд
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору